Differential Involvement of 5-HT1B/1D and 5-HT6 Receptors in Cognitive and Non-cognitive Symptoms in Alzheimer's Disease

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Neuropsychopharmacology

• Publication date

  2004-02-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1038/sj.npp.1300330PMID 14571255
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Potentiation of amphetamine-induced changes in dopamine and 5-HT by a 5-HT(6) receptor antagonist.

  2003cited by this paper
• Serotonin 1B knockout mice exhibit a task-dependent selective learning facilitation.

  2003cited by this paper
• Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist.

  2003cited by this paper
• Postmortem serotoninergic correlates of cognitive decline in Alzheimer's disease

  2002influential reference
• Effects of Typical and Atypical Antipsychotics and Receptor Selective Compounds on Acetylcholine Efflux in the Hippocampus of the Rat

  2002cited by this paper
• The medical benefit of 5-HT research.

  2002cited by this paper
• The Human Brain Revisited: Opportunities and Challenges in Postmortem Studies of Psychiatric Disorders

  2002cited by this paper
• Could the 5-HT1B receptor inverse agonism affect learning consolidation?

  2001cited by this paper
• The therapeutic potential of 5-HT6 receptor antagonists.

  2001cited by this paper
• SB-271046 (SmithKline Beecham).

  2001cited by this paper
• Pharmacological treatment of non-cognitive disturbances in dementia disorders.

  2001cited by this paper
• 5-HT6 receptor antagonists enhance retention of a water maze task in the rat

  2001cited by this paper
• Gene expression profiling in the post-mortem human brain--no cause for dismay.

  2001cited by this paper
• Psychosis of Alzheimer’s disease is associated with elevated muscarinic M2 binding in the cortex

  2001cited by this paper
• The 5-HT6 Receptor Antagonist SB-271046 Selectively Enhances Excitatory Neurotransmission in the Rat Frontal Cortex and Hippocampus

  2001cited by this paper
• The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus.

  2001cited by this paper
• A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze.

  2001cited by this paper
• Role of serotonin in memory impairment

  2000cited by this paper
• Psychotic Symptoms in Alzheimer's Disease Are Not Associated With More Severe Neuropathologic Features

  2000cited by this paper
• Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer’s disease prospectively assessed for behavioural changes

  2000cited by this paper
• 5-ht6 receptors as emerging targets for drug discovery.

  2000cited by this paper
• Characterization of [(125)I]-SB-258585 binding to human recombinant and native 5-HT(6) receptors in rat, pig and human brain tissue.

  2000cited by this paper
• In vivo effects of the 5‐HT6 antagonist SB‐271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5‐HT, glutamate and aspartate

  2000cited by this paper
• Characterization of [125I]‐SB‐258585 binding to human recombinant and native 5‐HT6 receptors in rat, pig and human brain tissue

  2000cited by this paper
• Acetylcholine in mind: a neurotransmitter correlate of consciousness?

  1999cited by this paper
• A review of central 5-HT receptors and their function.

  1999cited by this paper
• Differential sensitivity of 5-HT1B auto and heteroreceptors

  1999cited by this paper
• Neuropsychiatric Symptoms and Cholinergic Therapy for Alzheimer’s Disease

  1999cited by this paper
• Antibodies and Antisense Oligonucleotide for Probing the Distribution and Putative Functions of Central 5-HT6Receptors

  1999cited by this paper
• Investigation of stretching behaviour induced by the selective 5‐HT6 receptor antagonist, Ro 04–6790, in rats

  1999cited by this paper
• Natural history of aggressive behaviour in dementia

  1999cited by this paper
• Anxiogenic-like effects and reduced stereological counting of immunolabelled 5-hydroxytryptamine6 receptors in rat nucleus accumbens by antisense oligonucleotides.

  1999cited by this paper
• Serotonin in Aging, Late-Life Depression, and Alzheimer's Disease: The Emerging Role of Functional Imaging

  1998cited by this paper
• Cognitive functions of cortical acetylcholine: toward a unifying hypothesis.

  1997cited by this paper
• Effects of the 5-HT receptor antagonists GR127935 (5-HT1B/1D) and MDL100907 (5-HT2A) in the consolidation of learning.

  1997cited by this paper
• Behaviour changes in dementia 1: Point of entry data of a prospective study

  1997cited by this paper
• Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system.

  1997cited by this paper
• Behaviour changes in dementia 2: Are there behavioural syndromes?

  1997cited by this paper
• Role of 5-HT1B, 5-HT2A and 5-HT2C receptors in learning.

  1997cited by this paper
• The basis for behavioural disturbances in dementia.

  1997cited by this paper
• The serotonin hypothesis of aggression revisited.

  1997cited by this paper
• Characterization of human serotonin 1D and 1B receptors using [ 3H]-GR-125743, a novel radiolabelled serotonin 5HT1D/1B receptor antagonist

  1997cited by this paper
• Serotonin receptors in cognitive behaviors.

  1997cited by this paper
• The basis for behavioural disturbances in dementia.

  1996cited by this paper
• Behavioral and psychological signs and symptoms of dementia: implications for research and treatment. Cross-cultural perspectives: India.

  1996cited by this paper
• Presynaptic Serotonergic Markers in Community‐Acquired Cases of Alzheimer's Disease: Correlations with Depression and Neuroleptic Medication

  1996cited by this paper
• Colocalization of serotonin receptor subtypes 5‐HT2A, 5‐HT2C, and 5‐HT6 with neuropeptides in rat striatum

  1996cited by this paper
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD).

  1995cited by this paper
• Downregulation of muscarinic- and 5-HT1B-mediated modulation of [3H]acetylcholine release in hippocampal slices of rats with fimbria-fornix lesions and intrahippocampal grafts of septal origin.

  1995cited by this paper
• Evidence that 5‐hydroxytryptamine release in rat dorsal raphé nucleus is controlled by 5‐HT1A, 5‐HT1B and 5‐HT1D autoreceptors

  1995cited by this paper
• The frequency and troublesomeness of symptoms associated with Alzheimer's disease.

  1995cited by this paper
• Determination of the role of the 5-ht6 receptor in the rat brain: a study using antisense oligonucleotides.

  1995cited by this paper
• Neuropathological Correlates of Psychotic Phenomena in Confirmed Alzheimer's Disease

  1994cited by this paper
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  1994cited by this paper
• Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms

  1992cited by this paper
• Aggression, suicidality, and serotonin.

  1992cited by this paper
• Convergent cholinergic activities in aging and Alzheimer's disease.

  1992cited by this paper
• Monoaminergic and cholinergic synaptic markers in the nucleus basalis of meynert (nbM): Normal age‐related changes and the effect of heart disease and Alzheimer's disease

  1992influential reference
• The Present Behavioural Examination (PBE): the development of an interview to measure current behavioural abnormalities

  1992influential reference
• Monoamine neurotransmitters and their metabolites in brain regions in alzheimer's disease: A postmortem study

  1992influential reference
• 5-hydroxytryptamine1B receptors block the GABAB synaptic potential in rat dopamine neurons

  1992cited by this paper
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  1991cited by this paper
• Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases.

  1991influential reference
• Neuropathologic and neurochemical correlates of psychosis in primary dementia.

  1991cited by this paper
• Serotonin in Alzheimer‐type Dementia and Other Dementing Illnesses

  1990influential reference
• Normal densities of 5-HT3 receptor recognition sites in Alzheimer's disease.

  1990cited by this paper
• Disturbance of the 5-hydroxytryptamine metabolism in brains from patients with Alzheimer's dementia.

  1990influential reference
• Presynaptic regulation of acetylcholine release in the CNS.

  1989cited by this paper
• Monoaminergic innervation of the frontal and temporal lobes in Alzheimer's disease.

  1987influential reference
• Cholinergic terminals in rat hippocampus possess 5-HT1B receptors mediating inhibition of acetylcholine release.

  1986cited by this paper
• CAMDEX: A Standardised Instrument for the Diagnosis of Mental Disorder in the Elderly with Special Reference to the Early Detection of Dementia

  1986cited by this paper
• Nucleus Raphe Dorsalis in Dementia of the Alzheimer Type: Neurofibrillary Changes and Neuronal Packing Density

  1984cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• A rapid radiochemical method for the determination of choline acetyltransferase

  1975cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975influential reference

• Serotonergic Modulators in Alzheimer's Disease: A Hope in the Hopeless Condition

  2025cites this paper
• Targeting the serotonergic system in the treatment of neurodegenerative diseases—emerging therapies and unmet challenges

  2025cites this paper
• Serotonergic Regulation in Alzheimer’s Disease

  2025cites this paper
• Role of Ion Channels in Alzheimer’s Disease Pathophysiology

  2025cites this paper
• Neurotransmitters and Immunity: Molecular Mechanisms, Biological Functions, Diseases, and Potential Therapeutic Targets

  2025cites this paper
• Cerebrospinal fluid NPTX2 and [18F]FDG PET track serotonergic vulnerability to neurodegeneration in prodromal Alzheimer’s disease

  2025cites this paper
• Sumatriptan attenuates fear-learning despair induced by social isolation stress in mice: Mediating role of hypothalamic-pituitary-adrenal axis.

  2024cites this paper
• An overview of the pathophysiology of agitation in Alzheimer’s dementia with a focus on neurotransmitters and circuits

  2024cites this paper
• Monoamine alterations in Alzheimer’s disease and their implications in comorbid neuropsychiatric symptoms

  2024cites this paper
• Dorsal raphe nucleus–hippocampus serotonergic circuit underlies the depressive and cognitive impairments in 5×FAD male mice

  2024cites this paper
• Electroacupuncture Alleviates Memory Deficits in APP/PS1 Mice by Targeting Serotonergic Neurons in Dorsal Raphe Nucleus

  2024cites this paper
• Alzheimer Disease—Link With Major Depressive Disorder and Efficacy of Antidepressants in Modifying its Trajectory

  2024cites this paper
• Serotonergic dysfunction may mediate the relationship between alcohol consumption and Alzheimer’s disease

  2024cites this paper
• Molecular imaging of the association between serotonin degeneration and beta-amyloid deposition in mild cognitive impairment

  2023cites this paper
• Atypical antipsychotics antagonize GABA_A receptors in the ventral tegmental area GABA neurons to relieve psychotic behaviors

  2023cites this paper
• Human tau-overexpressing mice recapitulate brainstem involvement and neuropsychiatric features of early Alzheimer’s disease

  2023cites this paper
• Serotonin Degeneration and Amyloid-β Deposition in Mild Cognitive Impairment: Relationship to Cognitive Deficits

  2023cites this paper
• Recent Advancements in the Treatment of Alzheimer's Disease: A Multitarget-directed Ligand Approach.

  2023cites this paper
• Clinical Biomarkers and Novel Drug Targets to Cut Gordian Knots of Alzheimer's Disease.

  2022cites this paper
• How mind-body therapies might reduce pathological features of Alzheimer’s disease

  2022cites this paper
• Serotonin Receptor Gene Polymorphisms Are Associated with Cerebrospinal Fluid, Genetic, and Neuropsychological Biomarkers of Alzheimer’s Disease

  2022cites this paper
• Effects of Methionine treatment on epigenetic regulation of the 5-HT neurotransmission in 5xFAD mouse model of Alzheimer’s disease

  2022influential citation
• Migraine Pharmacological Treatment and Cognitive Impairment: Risks and Benefits

  2022cites this paper
• Neurotransmitter and Neurotransmitter Receptor Expression in the Saccule of the Human Vestibular System.

  2022cites this paper
• Alterations and interactions of subcortical modulatory systems in Alzheimer's disease.

  2021cites this paper
• Multifunctional Arylsulfone and Arylsulfonamide-Based Ligands with Prominent Mood-Modulating Activity and Benign Safety Profile, Targeting Neuropsychiatric Symptoms of Dementia

  2021cites this paper
• A Novel 5-HT1B Receptor Agonist of Herbal Compounds and One of the Therapeutic Uses for Alzheimer’s Disease

  2021cites this paper
• Neuropathology of the Brainstem to Mechanistically Understand and to Treat Alzheimer’s Disease

  2021cites this paper
• Serotonin modulation of hippocampal functions: From anatomy to neurotherapeutics.

  2021cites this paper
• From Hybrids to New Scaffolds: The Latest Medicinal Chemistry Goals in Multi-target Directed Ligands for Alzheimer’s Disease

  2020cites this paper
• Connecting Mind-Body Therapy-Mediated Effects to Pathological Features of Alzheimer’s Disease

  2020cites this paper
• Gene expression of serotonergic markers in peripheral blood mononuclear cells of patients with late-onset Alzheimer's disease

  2020cites this paper
• Chronic stress induced depressive-like behaviors in a classical murine model of Parkinson's disease.

  2020cites this paper
• Synthesis, in vitro evaluation and molecular docking of a new class of indolylpropyl benzamidopiperazines as dual AChE and SERT ligands for Alzheimer's disease.

  2020cites this paper
• Role of Hippocampal 5-HT6 Receptors in Glucocorticoid-Induced Enhancement of Memory Consolidation in Rats

  2020cites this paper
• Optogenetic stimulation of serotonin nuclei retrieve the lost memory in Alzheimer's disease

  2020cites this paper
• Imaging of the Serotonin System: Radiotracers and Applications in Memory Disorders

  2020cites this paper
• Tph2 Genetic Ablation Contributes to Senile Plaque Load and Astrogliosis in APP/PS1 Mice.

  2019cites this paper
• Theoretical and Experimental Approaches Aimed at Drug Design Targeting Neurodegenerative Diseases

  2019cites this paper
• Change in Expression of 5-HT6 Receptor at Different Stages of Alzheimer’s Disease: A Postmortem Study with the PET Radiopharmaceutical [18F]2FNQ1P

  2019cites this paper
• Thiamine and benfotiamine counteract ultrasound-induced aggression, normalize AMPA receptor expression and plasticity markers, and reduce oxidative stress in mice.

  2019cites this paper
• Serotonergic system, cognition, and BPSD in Alzheimer's disease.

  2019cites this paper
• Neuroprotective effects of 1`δ-1`-acetoxyeugenol acetate on Aβ(25-35) induced cognitive dysfunction in mice.

  2019cites this paper
• Monoaminergic System Modulation in Depression and Alzheimer’s Disease: A New Standpoint?

  2019cites this paper
• Comprehensive review of mechanisms of pathogenesis involved in Alzheimer's disease and potential therapeutic strategies.

  2019cites this paper
• Monoamines and their derivatives on GPCRs: potential therapy for Alzheimer's Disease.

  2019cites this paper
• Computational modeling and biomarker studies of pharmacological treatment of Alzheimer's disease

  2018cites this paper
• Biomarkers of agitation and aggression in Alzheimer's disease: A systematic review

  2018cites this paper
• Current Therapeutic Targets for Alzheimer's Disease

  2018cites this paper
• Established amyloid-β pathology is unaffected by chronic treatment with the selective serotonin reuptake inhibitor paroxetine

  2018cites this paper
• Neuropsychiatric Symptoms of Major or Mild Neurocognitive Disorders

  2018cites this paper
• Neurobiological determinants of depressive-like symptoms in rodents

  2018cites this paper
• The modern role of antipsychotics for the treatment of agitation and psychosis in Alzheimer’s disease

  2018cites this paper
• The neurochemistry of agitation in Alzheimer's disease: a systematic review.

  2018cites this paper
• Neurobiological determinants of depressive-like symptoms in rodents : A multifactorial approach

  2018cites this paper
• The effect of chronic stimulation of serotonin receptor type 7 on recognition, passive avoidance memory, hippocampal long-term potentiation, and neuronal apoptosis in the amyloid β protein treated rat

  2018cites this paper
• University of Southern Denmark Established amyloid-β pathology is unaffected by chronic treatment with the selective serotonin reuptake inhibitor paroxetine Severino,

  2018cites this paper
• Selective Vulnerability of Brainstem Nuclei in Distinct Tauopathies: A Postmortem Study

  2018cites this paper
• Astrocytic transporters in Alzheimer's disease.

  2017cites this paper
• Monoaminergic neuropathology in Alzheimer's disease

  2017cites this paper
• BDNF val66met Polymorphism Impairs Hippocampal Long-Term Depression by Down-Regulation of 5-HT3 Receptors

  2017cites this paper
• Frameworking memory and serotonergic markers

  2017cites this paper
• Multi-targeting Strategies for Alzheimer's Disease Therapeutics: Pros and Cons.

  2017cites this paper
• Branched-chain amino acids and Alzheimer’s disease: a Mendelian randomization analysis

  2017cites this paper
• The Effects of Centella asiatica Aqueous Extract on some Blood Parameters in Rat Model of Alzheimer's Disease

  2017cites this paper
• Drug Development in Alzheimer’s Disease: The Contribution of PET and SPECT

  2016cites this paper
• G-protein coupled receptors as therapeutic targets for neurodegenerative and cerebrovascular diseases.

  2016cites this paper
• Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases

  2016cites this paper
• The serotonergic system and cognitive function

  2016cites this paper
• Pharmacological Modulations of the Serotonergic System in a Cell-Model of Familial Alzheimer’s Disease

  2016cites this paper
• Biomarkers of aggression in dementia.

  2016cites this paper
• Serotonin 5-HT6 Receptor Antagonists in Alzheimer’s Disease: Therapeutic Rationale and Current Development Status

  2016cites this paper
• Galantamine therapy for alzheimer’s disease by introducing nanodrug delivery systems

  2016cites this paper
• Serotonin system in Alzheimer's disease : from a molecular and biomarkers perspective

  2016influential citation
• Analysis and Quantification of Physical Fatigue in Automobile Drivers: A Biomedical Approach

  2016cites this paper
• 5-HT1B and other related serotonergic proteins are altered in APPswe mutation.

  2015cites this paper
• Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer’s disease

  2015cites this paper
• Limited Effects of an eIF2α S51A Allele on Neurological Impairments in the 5xFAD Mouse Model of Alzheimer's Disease

  2015cites this paper
• Serotonin, neural markers, and memory

  2015cites this paper
• Combination of Pharmacophore Matching, 2D Similarity Search, and In Vitro Biological Assays in the Selection of Potential 5‐HT6 Antagonists from Large Commercial Repositories

  2015cites this paper
• Design, synthesis and pharmacological evaluation of indolylsulfonamide amines as potent and selective 5-HT6 receptor antagonists

  2015cites this paper
• Treatment Options in Alzheimer´s Disease: The GABA Story.

  2015cites this paper
• Serotonin 6 receptor controls alzheimer’s disease and depression

  2015cites this paper
• Serotonergic 5-HT6 Receptor Antagonists: Heterocyclic Chemistry and Potential Therapeutic Significance.

  2015cites this paper
• A systematic review of the clinical effectiveness and cost-effectiveness of sensory, psychological and behavioural interventions for managing agitation in older adults with dementia.

  2014cites this paper
• Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease.

  2014cites this paper
• Brain Region-Specific Monoaminergic Correlates of Neuropsychiatric Symptoms in Alzheimer's Disease

  2014cites this paper
• Behavioral and Psychological Symptoms in Alzheimer's Disease

  2014cites this paper
• Neurotransmitters and Memory

  2014cites this paper
• Serotonergic Therapies for Cognitive Symptoms in Alzheimer’s Disease: Rationale and Current Status

  2014cites this paper
• PET studies on the mechanism of monoaminergic drugs

  2014cites this paper
• Memory formation and memory alterations: 5-HT6 and 5-HT7 receptors, novel alternative

  2014cites this paper
• Distinct regional age effects on [11C]AZ10419369 binding to 5-HT1B receptors in the human brain

  2014cites this paper
• Specific Serotonergic Denervation Affects tau Pathology and Cognition without Altering Senile Plaques Deposition in APP/PS1 Mice

  2013cites this paper
• Apolipoprotein E gene, environmental risk factors, and their interactions in dementia among seniors

  2013cites this paper
• 5-HT6 receptors and Alzheimer's disease

  2013cites this paper
• The serotonergic system in ageing and Alzheimer's disease.

  2012cites this paper
• Age Effects on Serotonin Receptor 1B as Assessed by PET

  2012cites this paper
• Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.

  2012cites this paper
• Altered serotonergic neurotransmission as a main player in the pathophysiology of Alzheimer's disease : structural and ultrastructural studies in a triple transgenic mouse model of the disease

  2012cites this paper